



Rak v Sloveniji

Cancer in Slovenia

2019

letno poročilo
annual report

Rak v Sloveniji

Cancer in Slovenia

2019

Naslov *Title*

Rak v Sloveniji 2019 / Cancer in Slovenia 2019

Uredniški odbor *Editorial Board*

Vesna Zadnik, glavna urednica / editor-in-chief
Gorana Gašljevič, Marko Hočevar, Katja Jarm, Vera Pompe-Kirn,
Primož Strojani, Sonja Tomšič, Branko Zakotnik in Tina Žagar

Obdelava in analiza podatkov *Data Processing and Analysis*

Nika Bric, Tina Žagar, Katarina Lokar, Miran Mlakar in Mojca Birk

Oblikovanje in priprava za tisk *Design and Typesetting*

Nika Bric

Tisk *Printing*

Tiskarna Koštomaj, d.o.o.

Izdajatelj *Published by*

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Slovenian Cancer Registry

Naklada *Published in*

500 izvodov / 500 copies

Nasvet za citiranje *Recommended Reference*

Rak v Sloveniji 2019. Ljubljana: Onkološki inštitut Ljubljana,
Epidemiologija in register raka, Register raka Republike Slovenije, 2022.
Cancer in Slovenia 2019. Ljubljana: Institute of Oncology Ljubljana,
Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2022.

Osebe Registra raka Republike Slovenije *Staff of the Slovenian Cancer Registry*

Vesna Zadnik, vodja / head
Agata Čampa, Vesna Drolec, Maruška Ferjančič, Katja Hribar, Andrej Kirn, Katja Kolenc
Mokotar, Andrej Krašovec, Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, Polona
Rus, Darja Strle, Laura Šeneker Zupanc, Frančiška Škrlec, Polona Škulj, Urška Tomšič,
Boštjan Zavrtnik, Brigita Zore, Mojca Birk, Nika Bric, Ana Mihor, Miran Mlakar, Katarina
Lokar, Sonja Tomšič, Tina Žagar

Naslov *Correspondence to*

Register raka Republike Slovenije / Slovenian Cancer Registry
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
<http://www.onko-i.si/rrs/> <http://www.slora.si/>
<http://www.onko-i.si/eng/crs/> <http://www.slora.si/en/>

Uvodnik	6
<i>Editorial</i>	7
Podatki	8
Viri podatkov	8
Obdelava podatkov	9
Kakovost podatkov	10
<i>Data</i>	12
Data Sources	12
Data Processing	13
Data Quality	14
Rak v Sloveniji	15
Osnovni podatki o raku v Sloveniji 2019	16
Starost bolnikov	16
Časovni trend	16
Najpogostejši raki	18
Trend najpogostejših rakov	21
Redki raki	22
Preživetje	23
Primerjava z Evropo	26
<i>Cancer in Slovenia</i>	28
Basic figures on cancer in Slovenia 2019	28
Age of patients	28
Time trends	29
Most frequent cancers	29
Time trends for most frequent cancers	29
Rare cancers	30
Survival	30
Comparisons with Europe	31
Incidenca	32
Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2010–2019 in 2022.	32
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2010–2019 and 2022.	32
Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2019.	33
Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2019.	33
Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2019.	34
Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2019.	34

Tabela 4a:	Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2019.	38
Table 4a:	Incidence of microscopically (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2019.	38
Tabela 4b:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2019.	42
Table 4b:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2019.	42
Tabela 4c:	Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2019.	43
Table 4c:	Incidence of non-Hodgkin's lymphomas (NHL) by cancer site, Slovenia 2019.	43
Tabela 5:	Incidenca raka po stadiju, Slovenija 2019.	44
Table 5:	Cancer incidence by stage, Slovenia 2019.	44

Prevalenca 46

Tabela 6:	Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2019.	46
Table 6:	Prevalence of cancer patients by sex, Slovenia, December 31, 2019.	46

Umrljivost 47

Tabela 7:	Umrljivost za rakom po starosti in spolu, Slovenija 2019.	47
Table 7:	Cancer mortality by age and by sex, Slovenia 2019.	47

Preživetje 48

Tabela 8:	Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2015–2019.	48
Table 8:	One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2015–2019 by sex.	48

Zdravljenje 49

Tabela 9a:	Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2019, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.	49
Table 9a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	49
Tabela 9b:	Število bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2019, ki so bili v okviru prvega zdravljenja operirani, po ustanovi posega.	50
Table 9b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by surgery during their first treatment by treatment institution.	50
Tabela 9c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2019, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po ustanovi zdravljenja.	51
Table 9c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by systemic therapy during their first treatment by treatment institution.	51

Breme najpogostejših rakov	52
Vsi raki / All cancer sites (C00–C96)	52
Prostata / Prostate (C61)	53
Pljuča in sapnik / Lung and trachea (C33, C34)	54
Dojka / Breast (C50)	55
Debelo črevo in danka / Colon and rectum (C18–C20)	56
Koža, razen melanoma / Skin, non-melanoma (C44)	57
Kožni melanom / Malignant melanoma of skin (C43)	58
Glava in vrat / Head and neck (C00–C14, C30–C32)	59
Maternično telo / Corpus uteri (C54)	60
Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)	61
Pojmovnik	62
<i>Glossary</i>	63

Register raka Republike Slovenije (RRRS) je prepoznan kot eden najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od začetka deluje v okviru Onkološkega inštituta Ljubljana. Začetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje, profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporočili Svetovne zdravstvene organizacije zavedala, da je uspešnost in učinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoče objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v času. Leta 2020 smo praznovali 70. letnico neprekinjenega delovanja slovenskega Registra raka. Častitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani (www.onko-i.si/rrs) ter v posebej za to priložnost izdani brošuri.

Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje Državnega programa obvladovanja raka na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti). Dragoceni so za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov. Z natančnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru kliničnih registrov pa lahko, poleg zgoraj opisanega spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišničnega registra Onkološkega inštituta Ljubljana, ki že ves čas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogočajo podrobnejši pregled nad bolniki, zdravljenimi na inštitutu.

Redna letna poročila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben čas za izdajo letnega poročila nekoliko daljši, v poročilih zadnja leta objavljamo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2022). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga po začetnih črkah besed »Slovenija in rak« poimenovali SLORA. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoča primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in po svetu.

Vsem, ki ste kakorkoli prispevali k izdaji tega poročila, tako sodelavcem Registra raka kot tudi vsem zdravnikom in kliničnemu osebju po vsej državi, ki ste nam posredovali poročila o diagnozi in zdravljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem.



prof. dr. Vesna Zadnik, dr. med.
vodja Registra raka Republike Slovenije

Ljubljana, september 2022

The Slovenian Cancer Registry (SCR) is recognized as one of the oldest and best quality population-based cancer registries in Europe and the world. Founded in 1950, from the very beginning it has operated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, prof dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. In 2020, the Slovenian Cancer Registry celebrated the 70th anniversary of continuous operation. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Registry in all these years. Readers interested in learning more can find historical facts and anecdotes on our website (www.onko-i.si/eng/rrs) and in a brochure published specially for this occasion.

Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, together with mortality data collected and processed by the National Institute of Public Health, form the basis for assessing cancer burden in the country. The Registry's data are important for planning and evaluation of the National Cancer Control Programme for the primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as for planning for the facilities and resources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research and for evaluating the effectiveness of screening programmes. In addition, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment received by oncology patients. The Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nationwide Cancer Registry and is in large part also supplied with Registry's data, provides a more detailed overview of patients treated at the Institute.

Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional community and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, the projected cancer incidence for the year when the report is issued (i.e. for 2022 in this report) has in recent years been included in the report. Since 2010, our SLORA interactive web portal – www.slora.si – has also been up and running; its name is based on the initial letters of the words *Slovenija in rak* (Slovenia and cancer). It provides easy and quick access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of cancer burden in Slovenia with other countries in Europe and in the world.

On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff of the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment.




prof. Vesna Zadnik, MD, PhD
director of the Slovenian Cancer Registry

Ljubljana, September 2022

Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vključevanjem različnih virov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju različnih zbirk se uporablja enotni državni identifikator EMŠO.



Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravijo in spremljajo. Tradicionalno bolnišnice poročajo Registru raka na posebnem formularju *Prijavnica rakave bolezni*. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Univerzitetni Kliniki Golnik zbirajo podatke za *Prijavnico* v lastnem bolnišničnem registru ter jih od tam v Register raka posredujejo elektronsko; v ostalih bolnišnicah *Prijavnice* izpolnjujejo zdravniki, ki bolnika obravnavajo, ali pooblaščen osebje. Skladno s cilji Državnega programa obvladovanja raka 2017–2021 smo v letu 2019 začeli uvajati tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Registru raka posredujejo seznam bolnikov, ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno poročanje s *Prijavnicami* tako postopoma ukinjamo. Za zbolele v letu 2019, ki so prikazani v tem poročilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem kliničnem centru Maribor, Pediatrični kliniki ter Kliničnem oddelku za hematologijo Univerzitetnega kliničnega centra Ljubljana.

Dopolnilni vir podatkov Registra raka so podatkovna zbirka o vzrokih smrti, ki jo upravlja Nacionalni inštitut za javno zdravje, ter podatki o diagnosticiranih rakah, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojke in Svit za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne analize prostorske

razporeditve raka nam omogočata točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi prebivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi o začasnem naslovu, kot je upoštevano v pripravi števila prebivalcev po klasični »statistični« definiciji.

Pri izračunavanju in interpretiranju večine kazalnikov bremena raka so poleg podatkov o bolnikih ključni tudi nacionalni podatki o številu prebivalcev in njihovi starostni strukturi. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil pripravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julija posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2019 so prikazani v tabeli.

Obdelava podatkov

Podatke, prispelle v Register raka, posebej usposobljene medicinske sestre v procesu registracije kodirajo v skladu z mednarodnimi, nacionalnimi in internimi pravili.

Lokacija tumorja

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2019.
Population of Slovenia by age and sex on July 1st 2019.

Starostna skupina Age group	Skupaj All	Moški Males	Ženske Females
0-4	101.572	52.331	49.241
5-9	110.658	57.076	53.582
10-14	102.723	52.729	49.994
15-19	93.255	48.260	44.995
20-24	102.349	54.441	47.908
25-29	114.434	60.657	53.777
30-34	137.034	72.675	64.359
35-39	153.504	81.511	71.993
40-44	158.473	83.729	74.744
45-49	147.819	77.340	70.479
50-54	153.397	78.104	75.293
55-59	149.946	75.579	74.367
60-64	145.715	72.501	73.214
65-69	133.003	65.002	68.001
70-74	92.576	42.528	50.048
75-79	80.635	34.168	46.467
80-84	59.155	22.433	36.722
85+	53.062	14.771	38.291
Skupaj / Total	2.089.310	1.045.835	1.043.475

Vir: Statistični urad RS / Source: Statistical Office of the Republic of Slovenia

Morfologija tumorja

Pri uvrščanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj s topografsko šifro C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri neoplazmah krvotornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in pri kliničnem delu zamenjuje številne dodatne klasifikacije malignomov krvotornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011).

Stadij bolezni

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena (razsejana) bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik predtem ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že prisotni v oddaljenih bezgavkah ali organih (M1).

V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo po klasifikaciji FIGO, pri kožnem melanomu beležimo velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov


V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima posrednima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli.

Incidenca raka glede na način postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2019.
Cancer incidence according to basis of diagnosis, Slovenia 2019.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only		
			Število Number	%	Število Number	%	Število Number	%	
C00–C96	Vse lokacije All sites	Moški in ženske / Males and females	16080	15265	94,9	796	5,0	19	0,1
		Moški / Males	8395	7981	95,1	406	4,8	8	0,1
		Ženske / Females	7685	7284	94,8	390	5,1	11	0,1
C00–C14	Usta in žrelo / Mouth and pharynx	313	311	99,4	2	0,6	0	0,0	
C15	Požiralnik / Oesophagus	112	109	97,3	3	2,7	0	0,0	
C16	Želodec / Stomach	432	422	97,7	10	2,3	0	0,0	
C18	Debelo črevo / Colon	891	852	95,6	36	4,0	3	0,3	
C19–C20	Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction	468	458	97,9	10	2,1	0	0,0	
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	260	151	58,1	108	41,5	1	0,4	
C23–C24	Žolčnik in žolčevodi / Gallbladder and biliary tract	198	133	67,2	65	32,8	0	0,0	
C25	Trebušna slinavka / Pancreas	444	278	62,6	164	36,9	2	0,5	
C32	Grlo / Larynx	106	106	100,0	0	0,0	0	0,0	
C33–C34	Sapnik, sapnici in pljuča / Trachea, bronchus and lung	1605	1455	90,7	147	9,2	3	0,2	
C43	Maligni melanom kože / Malignant melanoma of skin	636	636	100,0	0	0,0	0	0,0	
C44	Druge maligne neoplazme kože / Skin, excl. melanoma	3609	3588	99,4	20	0,6	1	0,0	
C48–C49	Vezivno in mehko tkivo / Connective and soft tissue	76	74	97,4	2	2,6	0	0,0	
C50	Dojka / Breast	1583	1571	99,2	8	0,5	4	0,3	
C53	Maternični vrat / Cervix uteri	104	103	99,0	1	1,0	0	0,0	
C54	Maternično telo / Corpus uteri	390	387	99,2	3	0,8	0	0,0	
C56	Jajčnik / Ovary	163	151	92,6	12	7,4	0	0,0	
C61	Prostata / Prostate	1565	1530	97,8	35	2,2	0	0,0	
C62	Modo / Testis	115	115	100,0	0	0,0	0	0,0	
C64–C65	Ledvica z ledvičnim mehkom / Kidney with renal pelvis	394	358	90,9	36	9,1	0	0,0	
C67	Sečni mehur / Bladder	317	309	97,5	7	2,2	1	0,3	
C70–C72	Centralni in avtonomni živčni sistem / Central and autonomic nervous system	174	152	87,4	21	12,1	1	0,6	
C73	Ščitnica / Thyroid gland	202	202	100,0	0	0,0	0	0,0	
C81	Hodgkinov limfom / Hodgkin's lymphoma	63	63	100,0	0	0,0	0	0,0	
C82–C85	Ne-Hodgkinovi limfomi / Non-Hodgkin's lymphoma	480	480	100,0	0	0,0	0	0,0	
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	145	145	100,0	0	0,0	0	0,0	
C91–C95	Levkemije / Leukaemias	386	385	99,7	0	0,0	1	0,3	

Data Sources

Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases.



The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registries collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals Notification forms are filled in by the attending physicians or by the authorized staff. In accordance with the goals of the National Cancer Control Program 2017–2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting using Notification Forms will gradually be phased out. For patients diagnosed in 2019, whose data are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana.

Complementary sources of information for the Cancer Registry are death certificates that we obtain from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed cancers recorded in three national screening programs: ZORA for detection of precancerous and early

cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for detection of pre-cancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient's vital status (whether the person is alive, dead or lost to follow-up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accurately defined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis and not the temporary one, contrary to the standard "statistical" definition of the population used for calculating the number of inhabitants.

In addition to patient data, national population data, especially population size and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration in Slovenia. The census has been performed nearly every 10 years, however until 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, population data are available for any date at the Central Population Registry. In Annual Reports the population data on July 1 of the relevant year are used, obtained from the SiStat Database of the Statistical Office of the Republic of Slovenia. In the table on page 9, the population size of Slovenia in 2019 is presented, stratified by age and sex.

Data Processing

At the Cancer Registry, specially trained nurses code the data retrieved from Notifications of cancer in accordance with international, national and internal guidelines for cancer registration.

Tumour Location

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8th revision was used (ICD-8).

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well.

Tumour Morphology

When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the 3rd edition has been in use, including the 2011 updates. In this edition some changes were introduced in terms of morphology and behaviour coding and some new morphology codes were added for tumours that were not coded separately before 2001. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the 3rd edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant neoplasms, the former two being assigned to C96.7, while the polycythaemia is classified under the topography code C94 from the year 2001 on.

Development of molecular and genetic technologies has enabled more detailed classification of the type of cellular changes, found in malignant neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a larger number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of neoplasms of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and it replaced several other classifications of neoplasms of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification.

Cancer Staging

For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumour is also included in the localized stage. In cases of uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours only T1 tumour is included in the localized stage. In all these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). A disease with metastases in distant lymph nodes or organs is classified as a distant stage (M1).

Stage according to TNM or any other appropriate classification, if available, is also stored in the Cancer Registry database. Additionally, FIGO classification is used for gynaecological tumours, Clark's level and Breslow's thickness in skin melanoma, and Ann-Arbor System for lymphomas.

Data Quality


The quality of information can be directly assessed by the following internationally harmonized standard parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in the table on page 11.

Rak v Sloveniji

Za dodatne podatke o bremenu raka v Sloveniji in svetu obiščite: www.slora.si.

- Med rojenimi leta 2019 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk.
- Za rakom zboli letno okrog 16.000 Slovencev, več kot 8.000 moških in več kot 7.000 žensk, umre pa jih več kot 6.000, približno 3.500 moških in nekaj manj kot 3.000 žensk; med nami živi že več kot 120.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca).
- Kljub temu da se ogroženost z rakom zmerno večja, je največja pri starejših; med vsemi rakavimi bolniki, zbolelimi leta 2019, je bilo 64 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.
- Najpogostejši raki pri nas (kože, pljuč, dojke, prostate ter debelega črevesa in danke) so leta 2019 predstavljali 60 % vseh ugotovljenih rakov. Ti raki so povezani z nezdravim življenjskim slogom: kajenjem, čezmernim pitjem alkoholnih pijač, neustrezno prehrano, premalo gibanja in posledično prekomerno težo ter čezmernim sončenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Presejalni programi za rake, ki jih priporoča Svet Evropske unije in smo jih uvedli tudi v Sloveniji, so z zgodnjim odkrivanjem že zmanjšali umrljivost za rakom dojk, debelega črevesa in danke ter rakom materničnega vratu; pri slednjih dveh so zmanjšali tudi incidenco.
- Petletno čisto preživetje odraslih slovenskih bolnikov s katero koli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2015–2019, je bilo 58 %, bolnic pa 62 %.

Povzetek




Slika 1. Breme raka, Slovenija 2019.
Figure 1. Cancer burden, Slovenia 2019.

Osnovni podatki o raku v Sloveniji 2019

- Leta 2019 je v Sloveniji za rakom zbolelo 16.080 ljudi (8.395 moških in 7.685 žensk).
- Starostno standardizirana incidenčna stopnja (evropsko prebivalstvo) je bila 502,7/100.000; 565,1 pri moških in 461,2 pri ženskah. Med rojenimi leta 2019 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk.
- Leta 2019 je za rakom umrlo 6.285 Slovencev, 3.521 moških in 2.764 žensk. Med nami je živel 121.276 ljudi (55.790 moških in 65.486 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca).
- Med posameznimi slovenskimi regijami ne opažamo bistvenih razlik v bremenu raka.

Starost bolnikov


- Čeprav se ogroženost z rakom zmeroma večja, je največja v poznejši starosti; med vsemi rakavimi bolniki je leta 2019 kar 66 % moških in 61 % žensk zbolelo po dopolnjeni starosti 65 let. Manj kot polovico odstotka vseh rakavih bolezni je bilo ugotovljenih pri otrocih in mladostnikih (do 20. leta).
- Ker se slovensko prebivalstvo stara, je samo zaradi čedalje večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo. Ocenjujemo, da bomo leta 2022 zabeležili že 17.197 novih bolnikov.



Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2019.
Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2019.

Časovni trend


- V splošnem se groba incidenčna in umrljivostna stopnja raka večata.
- Groba incidenčna stopnja se je v zadnjih dvajsetih letih skoraj podvojila, v zadnjem desetletju se večja za 2,0 % povprečno letno (1,5 % pri moških in 2,6 % pri ženskah). Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih večala povprečno za 0,9 % letno, pri ženskah pa za 1,1 %.
- Več kot polovico tega povečanja lahko pripišemo staranju prebivalstva, saj z daljšo življenjsko dobo lahko tudi več ljudi dočaka to bolezen. Starostno standardizirana kumulativna incidenčna stopnja kaže, da se tveganje raka večja počasneje, pri moških se trend celo obrača navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (če ne upoštevamo staranja prebivalstva) manjša, predvsem od sredine devetdesetih let naprej, kar kaže na večjo uspešnost zdravljenja.



* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level

Slika 3. Groba letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2019.

Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2019.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level

Slika 4. Kumulativna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo v zadnjih 10 letih, Slovenija 1950–2019.


Figure 4. Cumulative incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2019.

Najpogostejši raki

- Rak ni ena sama bolezen, temveč več sto različnih. Te lahko vzniknejo v vseh tkivih in organih človeškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi različne bolj ali manj znane nevarnostne dejavnike.
- Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), pljuč, dojke, prostate ter raki debelega črevesa in danke obsegajo 60 % vseh novih primerov rakavih bolezni.
- Najpogostejši raki so povezani z nezdravim življenjskim slogom: kajenjem, čezmernim pitjem alkoholnih pijač, neustrezno prehrano, premalo gibanja in posledično prekomerno težo ter čezmernim sončenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Pri moških zavzemata nemelanomski kožni rak in rak prostate vsak približno petino vseh rakov, sledita pljučni rak ter rak debelega črevesa in danke. Pri ženskah je najpogostejši nemelanomski kožni rak, sledi rak dojke, ki predstavlja petino vseh rakov, nato pa še pljučni rak ter rak debelega črevesa in danke.
- Najpogostejši raki se v raznih življenjskih obdobjih pojavljajo različno. Pri otrocih in mladostnikih do 20. leta starosti so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živčnega sistema in limfomi. Mlajši odrasli (20–49 let) moški zbolevajo največ za rakom mod in kože, pri ženskah v tej starosti pa je na prvem mestu rak dojke.



Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2019.
Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2019.



*Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00-C14, C30-C32)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33-C34)



Debelo črevo in danka / Colorectum (C18-C20)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64-C65)

Ne-Hodgkinovi limfomi / Non-Hodgkin's lymphoma (C82-C85)

Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2019.

Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2019.



*Pojasnilo / Explanation:

Debelo črevo in danko / Colorectum (C18–C20)

Trebušna slinavka / Pancreas (C25)

Pljuča / Lung (C33–C34)

Kosti / Bone (C40–C41)

Koža, melanom / Skin, melanoma (C43)

Koža, razen melanoma / Skin, excl. melanoma (C44)

Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)

Glava in vrat / Head and neck (C00–C14, C30–C32)

Dojka / Breast (C50)

Maternični vrat / Cervix uteri (C53)

Maternično telo / Corpus uteri (C54)

Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)

Ščitnica / Thyroid gland (C73)

Hodgkinov limfom / Hodgkin's disease (C81)

Levkemije / Leukaemias (C91–C95)

Želodec / Stomach (C16)

Prostata / Prostate (C61)

Modo / Testis (C62)

Ledvica z ledvičnim mehkom / Kidney with renal pelvis (C64–C65)

Sečni mehur / Bladder (C67)


Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin's lymphoma (NHL) (C82–C85)

Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2015–2019.

Figure 6: Percentage distribution of leading cancer sites by age group and sex, Slovenia 2015–2019.

Trend najpogostejših rakov


- Med pogostejšimi rakavimi boleznimi pri moških se je incidenčna stopnja pljučnega raka večala vse do začetka novega tisočletja, ko se je ustalila pri vrednosti okoli 90/100.000.
- Pljučnega raka strmo prehitevata rak prostate (povečanje incidenčne stopnje za povprečno 0,7 % na leto) in nemelanomski kožni rak (povečanje za povprečno 5,1 % na leto). Izjemno povečanje incidence raka prostate v zadnjih dveh desetletjih ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri moških brez zdravstvenih težav in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate že dosegli.
- Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati ob upoštevanju sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (Svit). Groba incidenčna stopnja raka debelega črevesa in danke pri moških od leta 2010 pada za 3,0 % letno, pred tem pa je v desetletnem obdobju 1999–2008 naraščala vsako leto za 3,6 %. Povprečne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7a.
- Med pogostejšimi rakavimi boleznimi pri ženskah so se večale grobe incidenčne stopnje raka dojke (za 2,6 % povprečno letno), nemelanomskega kožnega raka (povečanje za povprečno 5,8 % letno), pljučnega raka (za 5,9 %) in raka materničnega telesa (za 1,9 %).
- Incidenčna stopnja raka materničnega vratu od uvedbe Državnega programa zgodnjega odkrivanja predrakavih sprememb in raka materničnega vratu (ZORA) strmo pada (za povprečno 3,7 % na leto v zadnjih desetih letih).
- Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit leta 2009 spreminja časovni trend pojavljanja raka debelega črevesa in danke – od leta 2010 groba incidenčna stopnja pada za 2,1 % letno, pred tem pa je med 1999 in 2008 naraščala vsako leto za 3,4 %.



* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level

Slika 7a. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2019.

Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in males, Slovenia 1950–2019.




Slika 7b. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2019.

Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in females, Slovenia 1950–2019.

Redki raki

- Poseben izziv so redke rakave bolezni (opredeljene kot tiste, ki se jih letno diagnosticira manj kot 6 novih primerov na 100.000 prebivalcev).
- Skupaj so redki raki v Sloveniji predstavljali približno petino vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo okrog 3.000 bolnikov.
- Za redke rake je značilno, da se v primerjavi s pogostejšimi večkrat pojavljajo pri otrocih in mladostnikih.
- Kot pri vseh redkih boleznih se tudi pri redkih rakih spopadamo s podobnimi težavami: pozno in težko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni široko dostopno. Da bi uspešno obvladovali redke rake, je pomembno, da njihovo breme natančno spremljamo, ter da vse države sprejmejo smernice in določijo referenčne centre za diagnostiko in zdravljenje teh bolnikov.




Preživetje

- Petletno čisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2015–2019, je bilo že 58,1 %, pri ženskah pa 61,8 %.
- Več kot 80 % je bilo čisto 5-letno preživetje pri moških z rakom mod, prostate, ščitnice, kožnim melanomom in Hodgkinovo boleznijo, pri ženskah pa pri bolnicah z rakom ščitnice, kožnim melanomom, rakom dojke, Hodgkinovo boleznijo in rakom materničnega telesa.
- V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov, zbolelih med letoma 1997 in 2016. Rezultati analize so na voljo v publikaciji *Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji* (Zadnik et al., 2020), ki je v digitalni obliki dostopna na www.onko-i.si/rrs. Glavni zaključki so:


1. Preživetje slovenskih bolnikov z rakom se s časom povečuje. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno čisto preživetje povečalo za 11 odstotnih točk. Občutno večja je rast pri moških, kjer se je petletno čisto preživetje povečalo za 17 odstotnih točk (iz 38 % na 55 %). Pri ženskah je petletno čisto preživetje zraslo za 6 odstotnih točk (iz 54 % na 60 %).
2. Ključni dejavniki za preživetje bolnikov z rakom so še vedno starost, stadij ob diagnozi in ustrezno zdravljenje. Petletno čisto preživetje je najmanjše pri starejših od 75 let, vendar se je tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih točk. Petletno čisto preživetje bolnikov z omejenim stadijem se je v 20 letih povečalo za 10 odstotnih točk; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje.
3. Pri obeh spolih se je v zadnjih 20 letih značilno povečalo preživetje pri treh pogostih rakah: raku na debelem črevesu in danki (za 14 odstotnih točk iz 48 % na 62 %), kožnem melanomu (za 12 odstotnih točk iz 79 % na 91 %) ter pri pljučnem raku (za 8 odstotnih točk iz 10 % na 18 %). Rezultati odražajo zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju.
4. Občuten je tudi napredek pri obeh najpogostejših rakah, raku dojke pri ženskah in raku prostate pri moških: petletno čisto preživetje bolnic z rakom dojke se je v zadnjih 20 letih povečalo za 10 odstotnih točk, petletno čisto preživetje bolnikov z rakom prostate pa celo za več kot 20 odstotnih točk. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekritično uporabljali testiranje PSA, s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinično nemi ter tako z zgodnejšo diagnozo umetno podaljšali preživetje.
5. V skupino rakov, kjer napredka s časom ni opaziti ter pri katerih preživetje še vedno ostajaja slabo, pa sodijo rak trebušne slinavke, rak požiralnika, raki jeter, žolčnika in žolčevodov ter možganski tumorji.
6. V raziskavi CONCORD-3 smo primerjali petletna čista preživetja odraslih bolnikov s petnajstimi različnimi vrstami raka, zbolelimi med letoma 2010 in 2014 v 26 evropskih državah. Preživetje slovenskih bolnikov z rakom je v večini primerov pod evropskim povprečjem, kar nam daje dobro osnovo za nadaljnje izboljšave.
7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zbolevalo predvsem za levkemijami, tumorji osrednjega živčevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno preživetje otrok in mladostnikov, zbolelih za rakom, povečalo za 7 odstotnih točk (iz 79 % na 86 %).

Moški Males



Slika 9a. Petletno čisto preživetje (s 95 % intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2015-2019 in 2010-2014.

Figure 9a. Five-year net survival (with 95% confidence interval) for males diagnosed with selected cancers in periods 2015-2019 and 2010-2014.



Slika 9b. Petletno čisto preživetje (s 95 % intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2015–2019 in 2010–2014.


Figure 9b. Five-year net survival (with 95% confidence interval) for females diagnosed with selected cancers in periods 2015–2019 and 2010–2014.

Primerjava z Evropo

- Po ocenah Evropskega informacijskega sistema za raka (<https://ecis.jrc.ec.europa.eu/>) je bila Slovenija leta 2020 po incidenčni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (616/100.000) na osmem mestu med 27 evropskimi državami. Večjo incidenco so imele Irska, Danska, Nizozemska, Belgija, Ciper, Madžarska in Francija.
- Po umrljivostni stopnji smo na sedmem mestu, večjo umrljivost so imeli Slovaška, Poljska, Ciper, Madžarska, Hrvaška in Danska.

Ocena incidence po državah Estimated incidence by country


EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2020
EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2020



Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidenčna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020.
Figure 10a. Estimated age-standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2020.

Ocena umrljivosti po državah Estimated mortality by country

EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2020
EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2020



Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020.
Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2020.

Cancer in Slovenia

For additional information on the burden of cancer in Slovenia and in the world, visit: www.slora.si. Figures are available on pages 15–27.

Summary

- Among those born in 2019, one in two men and one in three women are expected to develop cancer by the age of 75.
- Every year around 16,000 Slovenians (more than 8,000 men and more than 7,000 women) are diagnosed with cancer and over 6,000 (about 3,500 men and just under 3,000 women) die of cancer. Currently, there are already over 120,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence).
- The risk of developing cancer increases gradually with age and is highest among the elderly population; of all cancer patients diagnosed in 2019, 64% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people.
- In 2019, the most frequent cancers in Slovenia (skin, lung, breast, prostate, and colorectal) accounted for 60% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle: smoking, excessive alcohol consumption, unhealthy diet, lack of physical activity and consequential overweight and obesity, and excessive sun exposure – primary prevention measures should be in place with the aim to reduce their burden.
- Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia have already lowered mortality from breast, colorectal and cervical cancer through early detection; cancer incidence for colorectal and cervical cancers has also been reduced.
- The five-year net survival of adult Slovenian patients with any type of cancer (excluding non-melanoma skin cancer) who were diagnosed in the 2015–2019 period was 58% in men and 62% in women.

Basic figures on cancer in Slovenia 2019

- In 2019, 16,080 people (8,395 men and 7,685 women) were diagnosed with cancer in Slovenia.
- The age-standardized incidence rate (European standard population) was 502.7/100,000; 565.1 in men and 461.2 in women. Among those born in 2019, one in two men and one in three women are expected to develop cancer by the age of 75.
- In 2019, 6,285 Slovenians died of cancer, 3,521 men and 2,764 women. There were 121,276 people alive in Slovenia (55,790 men and 65,486 women) who had at some point during their lifetime been diagnosed with cancer (prevalence).
- There are no significant differences in the burden of cancer between regions of Slovenia.

Age of patients

- Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2019, as many as 66% men and 61% women were diagnosed with cancer after the age of 65. Less than half a percent of all cancers were diagnosed in children and adolescents (up to 20 years of age).

- As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. We estimate that in 2022, there will have been as many as 17,197 newly diagnosed cancer patients.

Time trends

- In general, the crude incidence and mortality rates of cancer are increasing.
- The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 2.0% per year over the last decade (by 1.5% in men and 2.6% in women). The crude mortality rate has increased on average by 0.9% per year in men over the last 10 years and by 1.1% in women.
- More than half of this increase can be attributed to an ageing population, as longer life expectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment.

Most frequent cancers

- Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment, and outcome, and are also associated with different, more or less established risk factors.
- The five most frequent cancers in Slovenia – skin (excluding melanoma), lung, breast, prostate and colorectal – account for 60% of all new cancer cases.
- The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden.
- In men, prostate cancer and non-melanoma skin cancer account for around one-fifth of all cancers each, followed by lung and colorectal cancer. In women, non-melanoma skin cancer is the most frequent cancer, followed by breast cancer, which accounts for one-fifth of all cancer cases. The following most frequent cancer sites in women are colorectal and lung cancer.
- The most frequent cancers differ according to age. In children and adolescents aged under 20 years leukaemias are the most frequent, followed by tumours of the central and autonomic nervous system and lymphomas. Young adult men are most often diagnosed with testicular cancer, while in young women breast cancer is ranked first.

Time trends for most frequent cancers

- Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 2000s, when it stabilized at around 90/100,000.
- Lung cancer is outranked by the steep rising rates of prostate cancer (crude incidence rate increases at the rate of 0.7% per year on average) and non-melanoma skin cancer (an increase of 5.1% per year on average). The dramatic increase in the incidence of prostate cancer over the past two decades is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years

indicate that we have already reached the peak incidence of prostate cancer.

- Time trends in the incidence of colorectal cancer must also be interpreted by taking into account changes in diagnostics – in 2009 Slovenia introduced the national screening and early detection programme for colorectal cancer (Svit). The crude incidence rate of colorectal cancer in men decreased by 3.0% per year from 2010 on, but it was on the rise in 1999–2008 (3.6% on average annually). Average annual percentage changes are shown next to the incidence curves in Figure 7.
- Among the more frequent cancers in women, crude incidence rates have been increasing for breast cancer (by 2.6% on average per year), skin, excluding melanoma (by 5.8% on average per year), lung cancer (by 5.9% on average per year) and corpus uteri cancer (by 1.9% on average per year).
- The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 3.7% per year in the last ten years).
- Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – the crude incidence rate of colorectal cancer in women decreased by 2.1% per year from 2010 on, but it was on the rise in the 1999–2008 period (3.4% on average annually).

Rare cancers

- A particular challenge is posed by rare cancers (defined as those with less than six new cases per 100,000 per year).
- In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year.
- As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents.
- Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for diagnostics and treatment of such patients.

Survival

- The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2015 and 2019 was 58.1%, while in women it was 61.8%.
- The five-year net survival was over 80% in men with testicular cancer, prostate cancer, thyroid cancer and skin melanoma, and in women with thyroid cancer, skin melanoma, breast cancer, Hodgkin's disease and uterine cancer.
- In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication *Survival of cancer patients, diagnosed in 1997–2016 in Slovenia* (Zadnik et al., 2021) which is also available in digital format at www.onko-i.si/eng/crs. Main conclusions are on the next page.

1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%).
2. Age and stage at diagnosis are still key factors when it comes to survival of cancer patients. Five-year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. Five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; survival of patients with distant disease has not improved.
3. For both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), skin melanoma (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). This improvement is due to earlier diagnosis and advances in systemic treatment.
4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased by 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased for over 20 percentage points. The improvement in prostate cancer survival is probably not real, since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease.
5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers as well as brain tumours.
6. In the CONCORD-3 study, five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements.
7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemias, central nervous system tumours and lymphomas, and have a better five-year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five-year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%).

Comparisons with Europe

- In 2020, according to the estimates of the European Cancer Information System (<https://ecis.jrc.ec.europa.eu/>) Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (616/100,000). Ireland, Denmark, the Netherlands, Belgium, Cyprus, Hungary and France had a higher incidence.
- We are in seventh place in terms of mortality, led by Slovakia, Poland, Cyprus, Hungary, Croatia and Denmark.

Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2010–2019 in 2022.
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2010–2019 and 2022.

Šifra MKB	Primarna lokacija	Spol	Povprečne letne opazovane vrednosti 2010–2014		Povprečne letne opazovane vrednosti 2015–2019		Ocena za 2022			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število s 95 % napovednim intervalom		Incidenčna stopnja na 100.000 s 95 % napovednim intervalom	
							Number	Incidence rate per 100,000	Number	Incidence rate per 100,000
C00–C96	Vse lokacije All sites	M+ž M ž	13861 7576 6285	674,3 744,4 605,4	15565 8346 7219	751,7 810,5 693,5	17197 9046 8151	16847–17546 8786–9306 7917–8385	816 855 777	800–833 831–880 754–799
C00–C14	Usta in žrelo Mouth and pharynx	M ž	275 73	27,0 7,0	266 81	25,9 7,8	247 82	206–288 58–106	23 8	20–27 6–10
C15	Požiralnik Oesophagus	M ž	74 15	7,3 1,5	72 21	6,9 2,0	81 21	57–106 9–33	8 2	5–10 1–3
C16	Želodec Stomach	M ž	295 183	29,0 17,6	275 171	26,7 16,4	254 157	213–296 123–192	24 15	20–28 12–18
C18	Debelo črevo Colon	M ž	517 389	50,8 37,5	484 381	47,0 36,6	463 354	403–523 303–405	44 34	38–49 29–39
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M ž	411 231	40,4 22,2	328 189	31,9 18,2	266 153	225–307 122–183	25 15	21–29 12–17
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M ž	141 52	13,9 5,0	173 67	16,8 6,5	212 87	173–251 64–111	20 8	16–24 6–11
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M ž	75 104	7,3 10,0	93 102	9,1 9,8	120 98	89–151 70–125	11 9	8–14 7–12
C25	Trebušna slinavka Pancreas	M ž	184 177	18,1 17,0	215 202	20,8 19,4	262 217	218–307 178–256	25 21	21–29 17–24
C32	Grlo Larynx	M ž	94 12	9,2 1,2	91 13	8,9 1,2	86 16	62–110 5–27	8 2	6–10 0–3
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M ž	872 409	85,7 39,4	975 562	94,6 54,0	1038 713	946–1130 646–781	98 68	89–107 62–74
C43	Malignni melanom kože Malignant melanoma of skin	M ž	267 249	26,2 24,0	310 283	30,1 27,1	356 312	305–407 267–357	34 30	29–39 25–34
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M ž	1242 1232	122,0 118,7	1628 1638	158,0 157,3	2037 2060	1910–2164 1945–2175	193 196	181–205 185–207
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M ž	28 41	2,7 4,0	36 40	3,5 3,9	36 38	24–48 21–55	3 4	2–5 2–5
C50	Dojka Breast	M ž	14 1275	1,3 122,8	12 1454	1,1 139,7	14 1630	3–25 1526–1735	1 155	0–2 145–165
C53	Maternični vrat Cervix uteri	M ž	– 128	– 12,3	– 108	– 10,4	– 102	– 77–127	– 10	– 7–12
C54	Maternično telo Corpus uteri	M ž	– 327	– 31,5	– 363	– 34,9	– 399	– 346–451	– 38	– 33–43
C56	Jajčnik Ovary	M ž	– 166	– 16,0	– 149	– 14,3	– 142	– 111–173	– 14	– 11–16
C61	Prostata Prostate	M ž	1554 –	152,7 –	1676 –	162,8 –	1710 –	1601–1820 –	162 –	151–172 –
C62	Modo Testis	M ž	105 –	10,3 –	116 –	11,3 –	120 –	91–149 –	11 –	9–14 –
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M ž	251 132	24,6 12,7	275 134	26,7 12,9	298 145	252–344 112–178	28 14	24–33 11–17
C67	Sečni mehur Bladder	M ž	240 83	23,5 8,0	253 97	24,6 9,3	266 105	223–310 77–132	25 10	21–29 7–13
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M ž	83 68	8,2 6,6	103 72	10,0 6,9	119 76	89–149 52–99	11 7	8–14 5–9
C73	Ščitnica Thyroid gland	M ž	43 118	4,2 11,3	50 155	4,8 14,9	56 185	37–75 151–220	5 18	4–7 14–21
C81	Hodgkinov limfom Hodgkin's lymphoma	M ž	23 26	2,2 2,5	30 26	2,9 2,5	32 29	16–49 15–44	3 3	1–5 1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M ž	188 183	18,4 17,6	226 218	22,0 20,9	265 265	216–313 223–307	25 25	20–30 21–29
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M ž	69 69	6,7 6,6	81 63	7,9 6,1	89 63	63–115 41–85	8 6	6–11 4–8
C91–C95	Levkemije Leukaemias	M ž	176 132	17,3 12,7	197 158	19,1 15,1	217 181	177–257 146–216	21 17	17–24 14–21

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2019.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2019.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR* – World standard	SSS* – evropski standard ASR* – European standard	SSS* – slovenski standard ASR* – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	16080	769,6	353,0	502,7	597,8
		M	8395	802,7	386,8	565,1	685,6
		Ž	7685	736,5	331,2	461,2	538,1
C00–C14	Usta in žrelo Mouth and pharynx	M	237	22,7	12,1	17,0	18,9
		Ž	76	7,3	3,4	4,8	5,4
C15	Požiralnik Oesophagus	M	83	7,9	4,0	5,8	6,8
		Ž	29	2,8	1,1	1,6	2,0
C16	Želodec Stomach	M	269	25,7	11,8	17,9	21,9
		Ž	163	15,6	5,6	8,5	10,5
C18	Debelo črevo Colon	M	487	46,6	21,0	31,9	39,4
		Ž	404	38,7	14,7	21,6	26,2
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	292	27,9	13,5	19,8	23,6
		Ž	176	16,9	6,9	9,9	11,9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	176	16,8	8,0	11,7	14,2
		Ž	84	8,1	3,1	4,4	5,4
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	100	9,6	4,2	6,4	8,1
		Ž	98	9,4	2,6	4,3	5,5
C25	Trebušna slinavka Pancreas	M	238	22,8	10,6	15,8	19,2
		Ž	206	19,7	6,5	9,9	12,2
C32	Grlo Larynx	M	89	8,5	4,3	6,2	7,1
		Ž	17	1,6	0,8	1,1	1,3
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	1002	95,8	44,8	66,0	80,1
		Ž	603	57,8	24,2	34,7	40,7
C43	Maligni melanom kože Malignant melanoma of skin	M	318	30,4	16,2	22,8	26,8
		Ž	318	30,5	17,3	22,3	25,2
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	1810	173,1	76,9	118,2	147,2
		Ž	1799	172,4	66,7	97,2	116,6
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	41	3,9	2,3	3,0	3,4
		Ž	35	3,4	1,7	2,1	2,4
C50	Dojka Breast	M	15	1,4	0,7	1,0	1,1
		Ž	1568	150,3	78,9	107,2	120,9
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	104	10,0	6,5	8,2	9,0
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	390	37,4	17,2	24,2	28,4
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	163	15,6	7,8	10,7	12,3
C61	Prostata Prostate	M	1565	149,6	68,7	102,6	127,5
		Ž	–	–	–	–	–
C62	Modo Testis	M	115	11,0	11,0	11,4	12,2
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	266	25,4	13,2	18,5	21,7
		Ž	128	12,3	5,2	7,2	8,6
C67	Sečni mehur Bladder	M	238	22,8	10,1	15,4	19,1
		Ž	79	7,6	2,9	4,3	5,0
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M	92	8,8	5,0	6,8	8,0
		Ž	82	7,9	3,8	5,3	5,9
C73	Ščitnica Thyroid gland	M	52	5,0	3,3	4,2	4,4
		Ž	150	14,4	9,9	12,1	13,5
C81	Hodgkinov limfom Hodgkin's lymphoma	M	33	3,2	2,9	3,0	3,3
		Ž	30	2,9	2,5	2,7	2,9
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	226	21,6	10,8	15,3	18,6
		Ž	254	24,3	10,5	14,9	17,5
C90	Difuzni plazmocitomi in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	81	7,7	3,6	5,4	6,6
		Ž	64	6,1	2,2	3,3	4,2
C91–C95	Levkemije Leukaemias	M	196	18,7	10,5	13,9	16,3
		Ž	190	18,2	10,2	12,3	13,4

* SSS – starostno standardizirana incidenčna stopnja na 100.000
ASR – age standardized incidence rate per 100,000

Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2019.
Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2019.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74	
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+
C00 - C96	Vse lokacije All sites	M+Ž M Ž	16080 8395 7685	23 10 13	15 7 8	15 4 11	16 9 7	39 21 18	75 41 34	153 60 93	237 98 139	378 149 229	564 196 368	944 412 532	1333 692 641	2035 1137 898	2584 1556 1028	2201 1298 903	2247 1272 975	1758 881 877	1463 552 911	769,6 802,7 736,5	41,4 46,3 37,3
C00	Ustnica Lip	M Ž	15 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	3 0	2 0	2 0	1 2	3 0	2 1	1,4 0,3	0,1 0,0
C01	Baza jezika Base of tongue	M Ž	30 7	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	3 0	4 1	9 2	9 3	3 0	0 1	0 2	0 2	2,9 0,7	0,2 0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M Ž	25 11	0 0	0 0	0 0	0 0	1 0	1 0	1 0	1 1	0 1	1 1	0 1	11 1	2 0	3 2	3 2	0 3	2 1	2 1	2,4 1,1	0,1 0,0
C03	Dlesen Gum	M Ž	5 7	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 2	1 0	0 3	0 0	1 1	1 0	0 1	0,5 0,7	0,0 0,1
C04	Ustno dno Floor of mouth	M Ž	21 4	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	4 2	6 0	3 0	1 0	3 0	3 0	3 0	0 0	0 1	2,0 0,4	0,1 0,0
C05	Nebo Palate	M Ž	6 5	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	1 0	1 0	1 1	1 1	1 1	1 0	0 1	0 0	0,6 0,5	0,0 0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M Ž	9 9	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 1	0 2	2 1	3 2	1 2	1 1	1 0	1 1	0 0	0,9 0,9	0,1 0,1
C07	Parotidna žleza Parotid gland	M Ž	11 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	1 0	1 0	1 1	3 1	1 1	1 0	1 0	0 0	1 0	1,1 0,3	0,1 0,0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M Ž	2 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 0	0 0	0 1	0 1	0 0	0 0	0 0	0,2 0,2	0,0 0,0
C09	Tonzila Tonsil	M Ž	36 10	0 0	0 0	0 0	0 0	0 0	0 0	2 0	1 0	4 0	2 2	7 3	7 1	7 4	7 0	2 0	2 0	0 0	2 0	3,4 1,0	0,2 0,1
C10	Orofarinks Oropharynx	M Ž	29 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	4 0	7 3	8 1	3 1	2 0	2 1	2 0	2 0	0 0	2,8 0,5	0,2 0,0
C11	Nazofarinks Nasopharynx	M Ž	9 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	2 0	0 0	3 0	1 1	1 0	0 0	0 0	1 2	0 0	0 0	0,9 0,3	0,1 0,0
C12	Piriformni sinus Pyiform sinus	M Ž	21 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	5 1	5 0	4 0	2 0	2 0	2 0	1 0	0 0	2,0 0,2	0,1 0,0
C13	Hipofarinks Hypopharynx	M Ž	17 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	1 0	3 2	2 4	4 5	5 2	2 0	0 0	0 0	1,6 0,5	0,1 0,0
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0,1 0,0	0,0 0,0
C15	Požiralnik Oesophagus	M Ž	83 29	0 0	0 0	0 0	0 0	0 1	0 0	1 0	3 1	4 0	6 3	12 0	11 4	15 2	12 3	9 9	7 4	3 2	7,9 2,8	0,5 0,1	
C16	Želodec Stomach	M Ž	269 163	0 0	0 0	0 0	0 1	0 2	0 3	1 2	2 3	8 6	19 9	26 9	35 19	39 27	39 31	49 19	32 19	19 32	25,7 15,6	1,4 0,7	
C17	Tanko črevo Small intestine	M Ž	30 20	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 2	1 2	0 1	8 5	6 5	4 1	2 3	2 0	2 1	0 1	2,9 1,9	0,2 0,1	
C18	Debelo črevo Colon	M Ž	487 404	0 0	0 0	0 0	1 2	0 2	6 5	4 9	15 10	10 10	23 25	31 21	47 34	83 53	62 57	85 58	64 72	56 56	46,6 38,7	2,3 1,7	
C19	Rektosigmoidna zveza Rectosigmoid junction	M Ž	76 40	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 2	2 1	5 0	8 1	14 3	14 8	14 7	11 11	11 11	9 4	7,3 3,8	0,4 0,1	
C20	Rektum Rectum	M Ž	216 136	0 0	0 0	0 0	0 0	2 1	3 1	6 2	8 10	20 10	23 17	35 17	38 21	23 15	25 18	21 22	9 12	20,7 13,0	1,2 0,7		
C21	Anus in analni kanal Anus and anal canal	M Ž	3 23	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 1	0 2	0 3	0 2	2 2	1 4	0 4	0 1	0 3	0,3 2,2	0,0 0,1	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M Ž	176 84	0 1	0 0	0 0	0 1	0 0	1 0	0 1	1 1	2 0	7 1	13 3	33 9	43 15	34 8	21 24	15 11	6 9	16,8 8,1	1,1 0,3	
C23	Žolčnik Gallbladder	M Ž	19 37	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 1	0 0	0 0	1 5	6 7	4 8	4 8	2 8	0 7	1,8 3,5	0,1 0,1	
C24	Druge in neopredeljeni deli biliarnega trakta Biliary tract, other and unspec- ified parts	M Ž	81 61	0 0	0 0	0 0	0 0	0 0	1 0	2 0	0 0	0 0	3 0	5 2	9 5	17 7	11 9	14 10	11 13	8 15	7,7 5,8	0,4 0,2	
C25	Trebušna slinavka Pancreas	M Ž	238 206	0 0	0 0	0 0	0 0	0 2	3 0	3 0	4 1	13 8	20 2	36 11	42 27	37 18	30 37	27 35	21 43	22,8 19,7	1,3 0,7		

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74	
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	20	0	0	0	0	0	0	0	0	1	2	1	1	0	1	4	3	3	1	1,9	0,1
		Ž	24	0	0	0	0	0	0	0	1	0	0	0	0	0	2	5	10	3	1	2	2,3
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	10	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	6	1,0	0,0
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	3	1	0,8
C88	Malignne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	2	0	0,5	0,0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0,3	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	81	0	0	0	0	0	0	1	0	1	3	4	8	8	18	12	11	7	8	7,7	0,4
		Ž	64	0	0	0	0	0	0	0	0	0	1	0	2	10	11	16	8	6	10	6,1	0,3
C91.0	Limfoblastna levkemija Lymphoblastic leukaemia, acute	M	12	2	4	0	0	0	2	0	1	0	0	0	0	1	0	0	0	2	0	1,1	0,1
		Ž	18	5	4	0	0	0	0	0	1	0	1	2	2	0	0	1	0	0	2	1,7	0,1
C91.1- C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	84	0	0	0	0	0	0	0	2	1	3	6	5	13	14	14	12	11	3	8,0	0,5
		Ž	76	0	0	0	0	0	0	0	1	3	3	7	9	7	8	8	12	8	10	7,3	0,3
C92	Mieloična levkemija Myeloid leukaemia	M	81	0	1	0	0	0	0	0	1	1	5	7	2	6	19	13	12	10	4	7,7	0,5
		Ž	71	2	0	1	1	2	1	0	3	4	1	2	2	6	7	3	14	10	12	6,8	0,3
C93	Monocitna levkemija Monocytic leukaemia	M	4	1	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0,4	0,0	
		Ž	9	1	0	0	0	0	0	0	0	0	1	1	1	0	0	2	1	1	1	0,9	0,1
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	15	0	0	0	0	1	0	0	2	2	0	1	2	1	3	0	1	1	1	1,4	0,1
		Ž	13	0	0	0	0	0	0	0	0	1	0	1	0	2	2	1	4	2	0	1,2	0,1
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0,3	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	90	0	0	1	0	0	0	0	2	3	2	6	4	6	17	12	16	12	9	8,6	1,4
		Ž	108	1	1	1	1	1	1	4	3	1	3	1	3	5	14	11	23	17	17	10,4	0,4

Zgoraj ne vključeni:
Not included above:

D03	Melanom, in situ Melanoma, in situ	M	177	0	0	0	0	0	2	2	8	15	9	13	17	23	25	27	21	4	11	16,9	1,1
		Ž	165	0	0	0	0	1	2	4	11	17	12	17	10	15	25	16	18	11	6	15,8	1,0
D05	Dojka, in situ Breast, in situ	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0,1	0,0
		Ž	183	0	0	0	0	0	0	0	1	7	14	40	32	35	42	4	6	2	0	17,5	1,2
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	1059	0	0	0	1	85	174	185	185	139	103	63	41	36	31	9	4	1	2	101,5	8,2
D09.0	Sečni mehur, in situ Bladder, in situ	M	208	0	0	0	0	0	0	2	2	4	4	9	12	35	32	41	32	27	8	19,9	1,2
		Ž	74	0	0	0	0	0	0	0	1	1	0	2	8	8	15	13	9	10	7	7,1	0,4
D32.0, D42.0	Meninge, benigna neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	50	0	0	0	0	0	0	0	1	3	2	3	5	5	7	8	8	6	2	4,8	0,3
		Ž	115	0	0	0	0	0	0	4	2	9	9	11	7	12	17	11	13	13	7	11,0	0,6
D33.0- D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
		Ž	4	0	0	0	1	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0,4	0,0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	57	0	0	1	2	0	2	4	6	5	2	6	11	3	6	2	3	3	1	5,5	0,4
D43.0- D43.2	Možgani, neopredeljeno Central nervous system (CNS), uncertain or unknown	M	8	0	2	1	0	0	0	2	1	0	0	0	0	2	0	0	0	0	0	0,8	0,1
		Ž	8	0	1	0	0	0	0	0	0	0	0	1	0	0	2	0	0	1	3	0,8	0,0

Tabela 4a: Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2019.
 Table 4a: Incidence of microscopically (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2019.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																			
		Primary site (ICD code)																			
		C00-C80	C00	C01	C02	C03	C04	C05	C06	C07	C08	C09	C10	C11	C12	C13	C14	C15	C16	C17	C18
Vse vrste / All types	13986	18	37	36	12	25	11	18	14	4	46	32	12	23	22	1	109	422	50	852	
Small cell carcinoma	265	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
Non-small cell carcinoma	90	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1614	18	36	36	11	24	9	17	1	0	46	32	11	23	22	1	76	1	0	0	
Basal cell carcinoma	2976	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	333	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Adenocarcinoma	7191	0	0	0	1	0	2	1	8	2	0	0	0	0	0	0	32	380	29	839	
Other specified carcinomas	140	0	1	0	0	0	0	0	3	0	0	0	0	0	0	0	1	1	0	5	
Carcinoma, unspecified	125	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	0	4	
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	668	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	
Fibrosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
Angiosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
Other specified sarcomas	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Sarcoma, unspecified	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
Malignant complex mixed and stromal tumors	100	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0	34	19	2	
Malignant fibroepithelial tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dysgerminoma and seminoma	65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other malignant germ cell tumors	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant trophoblastic tumors	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gliomas	148	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Nadaljevanje —>
 Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00-C80	C19	C20	C21	C22	C23	C24	C25	C26	C30	C31	C32	C33	C34	C37	C38	C39	C40	C41
Vse vrste / All types	13986	112	346	26	151	41	92	278	3	13	14	106	1	1454	16	8	0	6	12	636
Small cell carcinoma	265	0	0	0	0	0	1	0	0	0	0	1	0	247	0	0	0	0	0	0
Non-small cell carcinoma	90	0	0	0	0	0	0	0	0	0	0	0	0	88	0	0	0	0	0	0
Squamous cell carcinoma	1614	0	1	23	0	1	0	0	0	4	10	102	1	344	1	0	0	0	0	0
Basal cell carcinoma	2976	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	333	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Adenocarcinoma	7191	112	339	3	147	35	87	252	1	5	2	0	0	727	1	0	0	0	0	0
Other specified carcinomas	140	0	2	0	0	2	1	6	1	2	1	0	0	32	0	0	0	0	0	0
Carcinoma, unspecified	125	0	3	0	1	3	3	19	1	0	0	2	0	13	0	0	0	0	0	0
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	13	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	668	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	636
Fibrosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0
Fibrohistiocytic sarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Liposarcoma	20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
Angiosarcoma	8	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	3	0
Ewing sarcoma/PNET	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
Other specified sarcomas	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	29	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Malignant complex mixed and stromal tumors	100	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Malignant fibroepithelial tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	65	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Other malignant germ cell tumors	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Malignant trophoblastic tumors	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	148	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0
Malignant tumor, unspecified	4	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00–C80	C44	C45	C46	C47	C48	C49	C50	C51	C52	C53	C54	C55	C56	C57	C58	C60	C61	C62
Vse vrste / All types	13986	3588	43	1	4	21	53	1571	58	8	103	387	4	151	52	0	18	1530	115	
Small cell carcinoma	265	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	
Non-small cell carcinoma	90	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1614	576	0	0	0	0	0	0	47	6	84	0	0	1	0	0	17	0	0	
Basal cell carcinoma	2976	2970	0	0	0	0	0	0	4	0	1	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	333	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	
Adenocarcinoma	7191	24	0	0	0	5	0	1521	4	1	17	308	0	131	51	0	0	1524	0	
Other specified carcinomas	140	1	0	0	0	0	0	15	0	0	1	50	1	3	1	0	0	2	0	
Carcinoma, unspecified	125	2	0	0	0	0	0	31	0	0	0	0	0	2	0	0	1	0	0	
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	668	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	
Fibrosarcoma	12	0	0	0	0	1	8	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	10	7	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	20	0	0	0	0	10	7	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	18	3	0	0	0	1	7	0	0	0	0	2	3	0	0	0	0	0	0	
Rhabdomyosarcoma	4	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	5	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Angiosarcoma	8	1	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	1	0	
Kaposi sarcoma	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified sarcomas	4	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	
Sarcoma, unspecified	29	4	0	0	0	1	18	0	0	0	0	1	0	0	0	0	0	1	0	
Malignant complex mixed and stromal tumors	100	0	0	0	0	1	1	1	0	0	0	25	0	6	0	0	0	0	0	
Malignant fibroepithelial tumors	3	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	43	0	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	
Dysgerminoma and seminoma	65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	63	
Other malignant germ cell tumors	48	0	0	0	0	1	0	0	0	0	0	0	0	4	0	0	0	0	42	
Malignant trophoblastic tumors	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	
Malignant gliomas	148	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	5	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	4	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	4	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	

Nadaljevanje —>
Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																	
		Primary site (ICD code)																	
		C00–C80	C63	C64	C65	C66	C67	C68	C69	C70	C71	C72	C73	C74	C75	C76	C77	C78	C79
Vse vrste / All types	13986	5	330	28	17	309	1	15	4	145	3	202	8	4	5	36	28	6	74
Small cell carcinoma	265	0	1	0	0	5	0	0	0	0	0	0	0	0	0	5	0	0	2
Non-small cell carcinoma	90	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
Squamous cell carcinoma	1614	0	0	0	0	4	0	3	0	0	0	1	0	0	0	16	0	0	8
Basal cell carcinoma	2976	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	333	0	0	23	17	288	1	0	0	0	0	0	0	0	0	0	0	0	1
Adenocarcinoma	7191	0	321	0	0	2	0	0	0	0	0	196	1	3	3	13	23	3	35
Other specified carcinomas	140	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	3
Carcinoma, unspecified	125	0	2	5	0	9	0	0	0	0	0	0	0	0	0	2	4	0	13
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	5	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0
Malignant melanoma	668	0	0	0	0	0	0	11	1	0	0	0	0	0	0	0	0	3	9
Fibrosarcoma	12	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	20	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Rhabdomyosarcoma	4	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	4	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	4	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	29	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Malignant complex mixed and stromal tumors	100	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Malignant fibroepithelial tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	65	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Other malignant germ cell tumors	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	148	0	0	0	0	0	0	0	0	145	3	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	4	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

Tabela 4b:

Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2017, Slovenija 2019.

Table 4b:

Incidence of malignant neoplasms of lymphoid tissue according to 2017 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2019.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
Vse vrste All types	Moški in ženske / Males and females	889
	Moški / Males	441
	Ženske / Females	448
9727, 9728, 9835, 9836, 9811-9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	27
9727, 9835, 9811	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	22
9812, 9814	Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities	5
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	5
9729, 9837	Limfoblastni limfom T / levkemija T T Lymphoblastic lymphoma / leukaemia	5
9591-9597, 9670-9699, 9712, 9731-9738, 9760-9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	739
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	157
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	16
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	12
9940	Dlakastocelična levkemija Hairy cell leukaemia	9
9671	Limfoplazmatski limfom Lymphoplasmacytic lymphoma	8
9761	Waldenströmova makroglobulinemija Waldenström macroglobulinemia	8
9732, 9733	Multipli mielom Plasma cell myeloma	138
9731, 9734	Solitarni kostni in zunajkostni plazmatsom Solitary plasmacytoma of bone and extrasosseous	7
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	52
9699, ekstranodalni	B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal	32
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	5
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	52
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	16
9597	Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma	2
9673	Limfom plaščnih celic Mantle cell lymphoma	35
9680	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL ČZS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	177
9687	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	6

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	3
9596	Sestavljeni (kompozitni) Hodgkinov in non-Hodgkinov limfom Composite Hodgkin and non-Hodgkin lymphoma	2
9712	Intravaskularni velikocelični B-celični limfom Intravascular large B-cell lymphoma	1
9688	Velikocelični B-celični limfom bogat z limfociti T in histiociti T-cell/histiocyte rich large B-cell lymphoma	1
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	47
9827, 9831, 9834, 9948	Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	3
9831	Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	3
9700, 9701, 9708, 9709, 9716-9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	11
9717	Limfom T z enteropatijo Enteropathy-associated T-cell lymphoma	3
9700	Fungoidna mikoza Mycosis fungoides	2
9701	Sézaryjev sindrom Sézary syndrome	2
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	1
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	3
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	33
9702	Periferni limfom T (BDO- in ALK-negativen ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	19
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	11
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	3
9650-9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	63
9659	HL z nodularno limfocitno prevladanco Nodular lymphocyte predominant HL	4
9650	Klasični HL Classical HL	2
9663, 9664	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	30
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	5
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	20
9653	Klasični HL, tip limfocitne depicije Lymphocyte-depleted classical HL	2
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia	4
9590	Maligni limfom, BDO Malignant lymphoma, NOS	4
9750-9759	Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	4
9751	Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS	4

BDO - brez drugih oznak / NOS - not otherwise specified, EBV - Epstein-Barr virus, ČZS - centralni živčni sistem / CNS - central nervous system, NK - natural killer cells, ALCL - anaplastični velikocelični limfom / anaplastic large cell lymphoma

Tabela 4c: Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2019.
Table 4c: Incidence of non-Hodgkin's lymphomas (NHL) by cancer site, Slovenia 2019.

Šifra MKB-8	Primarna lokacija	Vse starosti
ICD-8 code	Primary site	All ages
	Vsi NHL All NHL	480
140	Ustnica Lip	1
141	Jezik Tongue	2
142	Slinavke Salivary glands	8
143	Dlesni Gum	1
144	Ustno dno Floor of mouth	1
145	Usta, drugo Mouth, other parts	1
146	Orofarinks Oropharynx	10
151	Želodec Stomach	22
152	Tanko črevo Small intestine	4
153	Debelo črevo Colon	3
154	Rektum Rectum	1
157	Trebušna slinavka Pancreas	1
160	Nos, obnosne votline, drugo Nose, paranasal sinuses, other	4
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	6
170	Kosti Bone	2
171	Mehka tkiva Soft tissues	4
173	Druge maligne neoplazme kože Skin, excluding melanoma	12
174	Dojka Breast	5
183	Jajčnik, jajcevod, drugo Ovary, Fallopian tube, other	1
184	Nožnica, vulva, drugo Vagina, vulva, etc.	1
186	Modo Testis	2
188	Mehur Bladder	1
190	Oko Eye	6
191	Možgani Brain	9
192	Živčevje, drugo Nervous system, other	1
193	Ščitnica Thyroid gland	4
194	Endokrine žleze, druge Endocrine glands, other	1
202	Bezgavke Lymph nodes	366

Tabela 5: Incidenca raka po stadiju, Slovenija 2019.
Table 5: Cancer incidence by stage, Slovenia 2019.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznano Unknown **	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C00-C80	Moški in ženske / Males and females	14800	8240	55,7	3709	25,1	2703	18,3	148	1,0
	Vse lokacije / All sites	7764	4118	53,0	2043	26,3	1503	19,4	100	1,3
	Moški / Males	7036	4122	58,6	1666	23,7	1200	17,1	48	0,7
	Ženske / Females									
C00	Ustnica / Lip	18	17	94,4	1	5,6	0	0,0	0	0,0
C01	Baza jezika / Base of tongue	37	5	13,5	28	75,7	4	10,8	0	0,0
C02	Jezik, drugi deli / Tongue, other & unspecified parts	36	11	30,6	25	69,4	0	0,0	0	0,0
C03	Dlesen / Gum	12	2	-	10	-	0	-	0	-
C04	Ustno dno / Floor of mouth	25	7	28,0	18	72,0	0	0,0	0	0,0
C05	Nebo / Palate	11	9	-	2	-	0	-	0	-
C06	Usta, drugi deli / Mouth, other & unspecified parts	18	4	22,2	13	72,2	1	5,6	0	0,0
C07	Parotidna žleza / Parotid gland	14	6	-	7	-	1	-	0	-
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	4	2	-	1	-	1	-	0	-
C09	Tonzila / Tonsil	46	8	17,4	37	80,4	1	2,2	0	0,0
C10	Orofaring / Oropharynx	34	4	11,8	28	82,4	2	5,9	0	0,0
C11	Nazofaring / Nasopharynx	12	1	-	10	-	1	-	0	-
C12	Piriformni sinus / Piriform sinus	23	2	8,7	19	82,6	2	8,7	0	0,0
C13	Hipofaring / Hypopharynx	22	5	22,7	16	72,7	1	4,5	0	0,0
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	1	0	-	0	-	1	-	0	-
C15	Požiralnik / Oesophagus	112	14	12,5	57	50,9	40	35,7	1	0,9
C16	Želodec / Stomach	432	90	20,8	161	37,3	176	40,7	5	1,2
C17	Tanko črevo / Small intestine	50	17	34,0	21	42,0	12	24,0	0	0,0
C18	Debelo črevo / Colon	891	206	23,1	480	53,9	199	22,3	6	0,7
C19	Rektosigmoidna zveza / Rectosigmoid junction	116	21	18,1	63	54,3	32	27,6	0	0,0
C20	Rektum / Rectum	352	91	25,9	179	50,9	81	23,0	1	0,3
C21	Anus in analni kanal / Anus and anal canal	26	12	46,2	13	50,0	1	3,8	0	0,0
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	260	73	28,1	77	29,6	101	38,8	9	3,5
C23	Žolčnik / Gallbladder	56	7	12,5	11	19,6	38	67,9	0	0,0
C24	Druge in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	142	28	19,7	58	40,8	52	36,6	4	2,8
C25	Trebušna slinavka / Pancreas	444	49	11,0	152	34,2	239	53,8	4	0,9
C26	Druge in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	4	0	-	0	-	4	-	0	-
C30	Nosna votlina in srednje uho / Nasal cavity and middle ear	13	7	-	6	-	0	-	0	-
C31	Obnosni sinusi / Accessory sinuses	14	3	-	11	-	0	-	0	-
C32	Grlo / Larynx	106	58	54,7	44	41,5	4	3,8	0	0,0
C33	Sapnik / Trachea	1	0	-	1	-	0	-	0	-
C34	Sapnica in pljuča / Bronchus and lung	1604	292	18,2	450	28,1	844	52,6	18	1,1
C37	Timus / Thymus	16	10	62,5	2	12,5	4	25,0	0	0,0
C38	Srce, mediastinum, plevra / Heart, mediastinum, pleura	11	1	-	6	-	2	-	2	-
C39	Druge in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	-	0	-	0	-	0	-
C40	Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs	6	3	-	3	-	0	-	0	-
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	12	4	-	6	-	2	-	0	-
C43	Maligni melanom kože / Malignant melanoma of skin	636	462	72,6	155	24,4	17	2,7	2	0,3
C44	Druge maligne neoplazme kože / Skin, excl. melanoma	3609	3510	97,3	94	2,6	4	0,1	1	0,0
C45	Mezoteliom / Mesothelioma	43	18	41,9	17	39,5	7	16,3	1	2,3
C46	Kaposijev sarkom / Kaposi's sarcoma	1	1	-	0	-	0	-	0	-
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	4	2	-	1	-	0	-	1	-
C48	Peritonej in retroperitonej / Retroperitoneum and peritoneum	22	2	9,1	14	63,6	6	27,3	0	0,0
C49	Drugo vezivno in mehko tkivo / Other connective and soft tissue	54	19	35,2	31	57,4	4	7,4	0	0,0
C50	Dojka / Breast	1583	931	58,8	523	33,0	122	7,7	7	0,4

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznan Unknown**	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C51	Žensko zunanje spolovilo / Vulva	58	39	67,2	17	29,3	1	1,7	1	1,7
C52	Nožnica / Vagina	8	2	-	5	-	1	-	0	-
C53	Maternični vrat / Cervix uteri	104	46	44,2	49	47,1	9	8,7	0	0,0
C54	Maternično telo / Corpus uteri	390	267	68,5	88	22,6	27	6,9	8	2,1
C55	Maternica, neopredeljeno / Uterus, unspecified	6	0	-	1	-	5	-	0	-
C56	Jajčnik / Ovary	163	20	12,3	27	16,6	116	71,2	0	0,0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	53	5	9,4	13	24,5	35	66,0	0	0,0
C58	Posteljica / Placenta	0	0	-	0	-	0	-	0	-
C60	Penis / Penis	18	11	61,1	3	16,7	4	22,2	0	0,0
C61	Prostata / Prostate	1565	941	60,1	426	27,2	167	10,7	31	2,0
C62	Modo / Testis	115	87	75,7	13	11,3	15	13,0	0	0,0
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	5	3	-	2	-	0	-	0	-
C64	Ledvica razen meha / Kidney, excl. renal pelvis	364	224	61,5	64	17,6	73	20,1	3	0,8
C65	Ledvični meh / Renal pelvis	30	7	23,3	13	43,3	10	33,3	0	0,0
C66	Sečevod / Ureter	18	10	55,6	4	22,2	3	16,7	1	5,6
C67	Sečni mehur / Bladder	317	212	66,9	77	24,3	25	7,9	3	0,9
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	1	0	-	0	-	1	-	0	-
C69	Okno in očesni adneksi / Eye and adnexa	19	16	84,2	3	15,8	0	0,0	0	0,0
C70	Meninge / Meninges	4	3	-	0	-	1	-	0	-
C71	Možgani / Brain	167	166	99,4	0	0,0	0	0,0	1	0,6
C72	Hrbtni mozeg, možganski živci in drugi deli centralnega živčnega sistema (ČZS) Spinal cord, cranial nerves and other parts of central nervous system (CNS)	3	3	-	0	-	0	-	0	-
C73	Ščitnica / Thyroid gland	202	155	76,7	41	20,3	6	3,0	0	0,0
C74	Nadledvična žleza / Adrenal gland	10	6	-	2	-	2	-	0	-
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	4	3	-	1	-	0	-	0	-
C76	Druga in slabo opredeljena mesta / Other and ill-defined sites	14	0	-	9	-	5	-	0	-
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	40	0	0,0	0	0,0	2	5,0	38	95,0
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	55	0	0,0	0	0,0	55	100,0	0	0,0
C79	Metastaze, drugje / Metastases of other sites	14	0	-	0	-	14	-	0	-
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	120	0	0,0	0	0,0	120	100,0	0	0,0

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			I		II		III + IV		Neznan / Unknown	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C81	Hodgkinov limfom / Hodgkin's lymphoma	63	7	11,1	20	31,7	35	55,6	1	1,6
C82	Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin's lymphoma	159	43	27,0	23	14,5	89	56,0	4	2,5
C83	Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin's lymphoma	259	53	20,5	34	13,1	156	60,2	16	6,2
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	44	7	15,9	3	6,8	32	72,7	2	4,5
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	18	3	16,7	1	5,6	9	50,0	5	27,8

* Odstotki niso računani, če je število novih primerov manjše od 15
Percentages are not calculated when number of new cases is less than 15

** Vključeni tudi primeri, ki so registrirani samo iz zdravniških poročil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju
Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage

Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2019.
Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2019.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence Vsi / All
			<1	1-4	5-9	10+	
C00-C96	Vse lokacije All sites	M+Ž	13316	38234	32304	46331	121276
		M	6810	19552	16293	17956	55790
		Ž	6506	18682	16011	28375	65486
C00-C14	Usta in žrelo Mouth and pharynx	M	212	563	450	532	1757
		Ž	61	221	160	300	742
C15	Požiralnik Oesophagus	M	58	52	25	23	158
		Ž	18	11	8	12	49
C16	Želodec Stomach	M	176	353	290	414	1233
		Ž	103	234	196	363	896
C18	Debelo črevo Colon	M	393	1162	1137	1173	3865
		Ž	353	899	889	1215	3356
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	255	855	930	997	3037
		Ž	151	456	505	857	1969
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	100	121	34	24	279
		Ž	33	39	10	13	95
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	62	62	37	41	202
		Ž	41	69	40	47	197
C25	Trebušna slinavka Pancreas	M	131	100	33	26	290
		Ž	99	109	35	38	281
C32	Grlo Larynx	M	84	238	214	359	895
		Ž	17	31	29	59	136
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	606	928	402	410	2346
		Ž	410	740	289	227	1666
C43	Malignni melanom kože Malignant melanoma of skin	M	309	1037	920	1113	3379
		Ž	309	971	946	1824	4050
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	1762	5496	4335	4686	16279
		Ž	1773	5727	4539	5861	17900
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	38	76	65	211	390
		Ž	26	97	81	220	424
C50	Dojka Breast	M	15	32	39	35	121
		Ž	1516	4941	4548	8312	19317
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	94	312	402	2625	3433
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	358	1118	1093	2415	4984
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	135	292	276	913	1616
C61	Prostata Prostate	M	1498	5719	5105	3600	15922
		Ž	-	-	-	-	-
C62	Modo Testis	M	112	450	494	1622	2678
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	221	700	611	759	2291
		Ž	103	344	323	527	1297
C67	Sečni mehur Bladder	M	201	563	418	456	1638
		Ž	63	184	123	163	533
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	59	109	60	192	420
		Ž	50	61	47	149	307
C73	Ščitnica Thyroid gland	M	49	173	163	280	665
		Ž	144	586	527	1228	2485
C81	Hodgkinov limfom Hodgkin's lymphoma	M	30	94	88	376	588
		Ž	28	87	107	358	580
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	191	551	455	615	1812
		Ž	211	538	456	646	1851
C90	Difuzni plazmocitomi in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	68	180	86	63	397
		Ž	51	140	96	58	345
C91-C95	Levkemije Leukaemias	M	147	432	326	469	1374
		Ž	149	329	243	409	1130

* Pri posameznih lokacijah je pri prikazu prevalenca oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat
Person diagnosed with more than one cancer is included as a prevalent case in each cancer site, but for all sites together (C00-C96) each person is counted once only

Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2019. Vir: Nacionalni inštitut za javno zdravje
 Table 7: Cancer mortality by age and by sex, Slovenia 2019. Source: National Institute of Public Health

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age			
				0-19	20-49	50-74	75+
C00-C97	Vse lokacije All sites	M+Ž	6285	8	190	2872	3215
		M	3521	6	105	1738	1672
		Ž	2764	2	85	1134	1543
C00-C14	Usta in žrelo Mouth and pharynx	M	99	0	7	71	21
		Ž	33	0	1	17	15
C15	Požiralnik Oesophagus	M	63	0	3	41	19
		Ž	20	0	1	9	10
C16	Želodec Stomach	M	192	0	9	95	88
		Ž	120	0	4	30	86
C18	Debelo črevo Colon	M	244	0	6	95	143
		Ž	170	0	5	50	115
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	162	0	9	68	85
		Ž	98	0	2	34	62
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	172	0	4	109	59
		Ž	103	0	1	47	55
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	53	0	1	34	18
		Ž	70	0	0	23	47
C25	Trebušna slinavka Pancreas	M	221	0	8	126	87
		Ž	179	0	4	77	98
C32	Grlo Larynx	M	41	0	1	28	12
		Ž	4	0	0	2	2
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	784	0	5	498	281
		Ž	437	0	8	252	177
C43	Maligni melanom kože Malignant melanoma of skin	M	56	0	7	24	25
		Ž	59	0	5	20	34
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	33	0	1	4	28
		Ž	26	0	0	3	23
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	17	0	2	6	9
		Ž	18	0	2	11	5
C50	Dojka Breast	M	10	0	1	3	6
		Ž	433	0	20	176	237
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	44	0	9	22	13
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	73	0	3	31	39
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	120	0	5	68	47
C61	Prostata Prostate	M	445	0	1	123	321
		Ž	-	-	-	-	-
C62	Modo Testis	M	8	0	8	0	0
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehcom Kidney with renal pelvis	M	104	1	3	49	51
		Ž	52	0	0	17	35
C67	Sečni mehur Bladder	M	144	0	1	49	94
		Ž	50	0	0	9	41
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	86	1	16	46	23
		Ž	84	0	5	48	31
C73	Ščitnica Thyroid gland	M	6	0	0	3	3
		Ž	12	0	1	4	7
C81	Hodgkinov limfom Hodgkin's lymphoma	M	8	0	0	4	4
		Ž	9	0	0	2	7
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	107	0	6	45	56
		Ž	82	0	2	31	49
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	65	0	1	36	28
		Ž	66	0	1	25	40
C91-C95	Levkemije Leukaemias	M	113	1	2	52	58
		Ž	95	2	0	22	71

Tabela 8: Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2015–2019.

Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2015–2019 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje s 95 % intervalom zaupanja		Pet-letno preživetje s 95 % intervalom zaupanja	
			One-year survival with 95% confidence interval		Five-year survival with 95% confidence interval	
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	75,2	74,9–75,6	59,8	59,3–60,3
		M	73,8	73,3–74,3	58,1	57,4–58,8
		Ž	76,9	76,4–77,4	61,8	61,1–62,6
C00–C14	Usta in žrelo Mouth and pharynx	M	75,0	72,6–77,5	46,8	43,5–50,3
		Ž	83,4	79,6–87,4	64,2	58,4–70,7
C15	Požiralnik Oesophagus	M	40,0	35,2–45,6	12,1	8,6–16,9
		Ž	32,2	24,2–42,8	12,9	7,5–22,0
C16	Želodec Stomach	M	53,4	50,7–56,3	29,6	26,6–33,0
		Ž	50,9	47,5–54,6	32,8	29,2–37,0
C18	Debelo črevo Colon	M	79,2	77,4–81,0	63,7	60,9–66,7
		Ž	78,8	76,8–80,8	63,6	60,5–66,9
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	84,3	82,4–86,3	64,2	60,8–67,7
		Ž	80,0	77,3–82,8	61,4	57,2–65,8
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	36,2	33,0–39,7	10,8	8,5–13,7
		Ž	32,0	27,2–37,7	11,5	7,7–17,0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	36,8	32,6–41,7	13,8	10,6–18,1
		Ž	29,4	25,6–33,8	12,7	9,6–16,7
C25	Trebšna slinavka Pancreas	M	29,2	26,5–32,2	7,7	6,0–9,8
		Ž	27,1	24,5–30,1	8,9	7,1–11,1
C32	Grlo Larynx	M	87,1	83,8–90,6	64,5	58,8–70,7
		Ž	*		*	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	45,1	43,7–46,6	19,5	18,2–20,9
		Ž	54,1	52,2–56,0	26,4	24,6–28,5
C43	Malignni melanom kože Malignant melanoma of skin	M	97,0	95,7–98,2	90,0	86,9–93,1
		Ž	98,3	97,3–99,3	91,0	88,0–94,1
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	**		**	
		Ž	**		**	
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	75,6	69,2–82,6	55,9	47,6–65,7
		Ž	79,8	74,2–85,9	55,7	47,9–64,6
C50	Dojka Breast	M	*		*	
		Ž	96,8	96,3–97,3	87,3	86,0–88,7
C53	Maternični vrat Cervix uteri	M	-		-	
		Ž	84,3	81,1–87,6	72,1	67,8–76,7
C54	Maternično telo Corpus uteri	M	-		-	
		Ž	91,7	90,3–93,2	80,4	77,7–83,2
C56	Jajčnik Ovary	M	-		-	
		Ž	75,1	71,9–78,4	43,3	39,3–47,6
C61	Prostata Prostate	M	97,8	97,3–98,3	95,0	93,7–96,3
		Ž	-		-	
C62	Modo Testis	M	98,8	97,9–99,8	96,9	95,1–98,7
		Ž	-		-	
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	81,0	78,7–83,3	67,0	63,5–70,7
		Ž	76,4	73,0–80,0	64,6	59,6–69,9
C67	Sečni mehur Bladder	M	75,0	72,4–77,6	55,3	51,3–59,7
		Ž	66,7	62,3–71,3	48,7	43,1–54,9
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	46,4	42,3–51,0	19,0	15,6–23,1
		Ž	43,8	38,9–49,3	15,7	12,2–20,2
C73	Ščitnica Thyroid gland	M	95,6	92,7–98,5	89,5	83,9–95,5
		Ž	97,0	95,6–98,3	96,9	94,8–99,1
C81	Hodgkinov limfom Hodgkin's lymphoma	M	91,1	86,4–96,0	80,1	73,0–87,9
		Ž	91,6	86,7–96,8	83,6	75,9–92,1
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	76,3	73,7–79,1	65,3	61,6–69,3
		Ž	77,2	74,6–79,9	67,2	63,5–71,1
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	78,7	74,5–83,2	47,6	41,4–54,7
		Ž	77,8	73,0–82,8	43,1	36,3–51,2
C91–C95	Levkemije Leukaemias	M	71,7	68,7–74,7	53,3	49,3–57,6
		Ž	69,3	66,0–72,8	53,4	48,8–58,5

* Število v analizo vključenih bolnikov je v povprečju manjše od 15 na leto / Average number of patients included in the analysis is less than 15 annually

** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo

Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population

Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2019, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL).

Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given).

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemsko terapijo No. of treated by systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število (od tega OIL) Number (IOL only)	%**
C00-C96	Vse lokacije / All sites	16061	13168	82,0	10230	63,7	4816	30,0	3349 (2930)	20,9
C00-C14	Usta in žrelo Mouth and pharynx	313	282	90,1	169	54,0	21	6,7	206 (205)	65,8
C15	Požiralnik Oesophagus	112	69	61,6	18	16,1	26	23,2	51 (45)	45,5
C16	Želodec Stomach	432	280	64,8	200	46,3	133	30,8	56 (43)	13,0
C18	Debelo črevo Colon	888	759	85,5	726	81,8	230	25,9	8 (7)	-
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	468	402	85,9	330	70,5	175	37,4	170 (167)	36,3
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	259	100	38,6	40	15,4	54	20,8	4 (3)	-
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	84	42,4	70	35,4	40	20,2	4 (3)	-
C25	Trebušna slinavka Pancreas	442	205	46,4	101	22,9	143	32,4	22 (17)	5,0
C32	Grlo Larynx	106	100	94,3	53	50,0	7	-	75 (75)	70,8
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1602	1077	67,2	366	22,8	536	33,5	537 (460)	33,5
C43	Maligni melanom kože Malignant melanoma of skin	636	632	99,4	630	99,1	59	9,3	38 (38)	6,0
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3608	3578	99,2	3460	95,9	26	0,7	116 (116)	3,2
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	76	67	88,2	59	77,6	15	19,7	37 (36)	48,7
C50	Dojka Breast	1579	1530	96,9	1316	83,3	1425	90,2	1047 (792)	66,3
C53	Maternični vrat Cervix uteri	104	93	89,4	80	76,9	5	-	49 (48)	47,1
C54	Maternično telo Corpus uteri	390	362	92,8	341	87,4	85	21,8	149 (137)	38,2
C56	Jajčnik Ovary	163	140	85,9	119	73,0	114	69,9	2 (2)	-
C61	Prostata Prostate	1565	1163	74,3	782	50,0	438	28,0	187 (168)	11,9
C62	Modo Testis	115	115	100,0	115	100,0	66	57,4	0 (0)	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	394	310	78,7	272	69,0	44	11,2	15 (9)	3,8
C67	Sečni mehur Bladder	316	290	91,8	285	90,2	69	21,8	15 (14)	4,7
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	173	150	86,7	148	85,5	83	48,0	115 (115)	66,5
C73	Ščitnica Thyroid gland	202	194	96,0	188	93,1	190	94,1	128 (128)	63,4
C81	Hodgkinov limfom Hodgkin's lymphoma	63	59	93,7	2	-	57	90,5	22 (22)	34,9
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	480	347	72,3	47	9,8	274	57,1	123 (123)	25,6
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	145	120	82,8	5	-	114	78,6	27 (19)	18,6
C91-C95	Levkemije Leukaemias	385	175	45,5	1	-	173	44,9	7 (7)	-

* Število bolnikov zdravljenih s specifičnim onkološkim zdravljenjem v okviru prvega zdravljenja ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo med operacijo, sistemsko terapijo ali obsevanje)

Number of all treated patients with specific oncological treatment regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

Percentages are not calculated for less than 15 cases

Tabela 9b: Število bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2019, ki so bili v okviru prvega zdravljenja operirani*, po ustanovi posega.

Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by surgery during their first treatment* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00-C96	Vse lokacije All sites	16061	10230	855	294	305	2452	1493	1880	408	258	438	119	459	1114	155
C00-C14	Usta in žrelo Mouth and pharynx	313	169	8	0	1	116	0	40	2	0	2	0	0	0	0
C15	Požiralnik Oesophagus	112	18	0	0	0	14	0	4	0	0	0	0	0	0	0
C16	Želodec Stomach	432	200	5	6	6	83	12	68	5	2	0	0	1	8	4
C18	Debelo črevo Colon	888	726	58	49	72	188	66	99	35	29	27	16	38	26	23
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	468	330	19	16	31	73	61	48	12	3	11	0	18	35	3
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	259	40	0	0	0	24	0	16	0	0	0	0	0	0	0
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	70	2	4	5	34	0	21	0	0	2	0	0	2	0
C25	Trebušna slinavka Pancreas	442	101	0	0	4	62	1	33	0	0	0	0	0	0	1
C32	Grlo Larynx	106	53	0	0	0	40	0	13	0	0	0	0	0	0	0
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1602	366	0	0	0	102	1	88	0	0	0	2	0	166	7
C43	Malignni melanom kože Malignant melanoma of skin	636	630	66	32	28	135	30	82	18	17	35	4	8	139	36
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3608	3460	473	144	126	613	37	686	240	77	260	92	22	655	35
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	76	59	1	1	0	9	41	4	1	0	1	0	0	0	1
C50	Dojka Breast	1579	1316	23	0	0	0	944	266	0	52	0	0	26	1	4
C53	Maternični vrat Cervix uteri	104	80	6	1	1	44	4	7	2	1	1	2	2	0	9
C54	Maternično telo Corpus uteri	390	341	20	8	7	137	53	63	10	6	8	2	9	0	18
C56	Jajčnik Ovary	163	119	4	1	2	49	34	21	1	3	1	0	2	0	1
C61	Prostata Prostate	1565	782	95	17	5	170	1	79	38	29	33	0	252	61	2
C62	Modo Testis	115	115	13	0	2	66	1	10	5	8	4	0	6	0	0
C64-C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	394	272	7	3	3	90	4	76	14	16	19	0	35	4	1
C67	Sečni mehur Bladder	316	285	31	5	7	114	0	44	14	8	26	0	35	0	1
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	173	148	0	0	0	94	0	52	0	0	0	0	0	0	2
C73	Ščitnica Thyroid gland	202	188	15	0	0	25	134	9	0	0	0	0	0	3	2
C81	Hodgkinov limfom Hodgkin's lymphoma	63	2	0	0	0	1	1	0	0	0	0	0	0	0	0
C82-C85	ne-Hodgkinovi limfomi non-Hodgkin's lymphoma	480	47	0	0	3	16	12	6	2	3	2	0	2	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	145	5	0	0	0	4	0	1	0	0	0	0	0	0	0
C91-C95	Levkemije Leukaemias	385	1	0	0	0	0	0	1	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

Less than 30 patients were treated by surgery in individual institution

Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2019, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po ustanovi zdravljenja.
 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2019, that were treated by systemic therapy during their first treatment* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Univerzitetna klinika Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	16061	4816	91	158	27	467	2840	904	26	94	47	94	31	37
C00–C14	Usta in žrelo Mouth and pharynx	313	21	0	0	0	0	20	1	0	0	0	0	0	0
C15	Požiralnik Oesophagus	112	26	0	0	0	0	22	4	0	0	0	0	0	0
C16	Želodec Stomach	432	133	0	0	0	12	61	53	0	1	0	5	0	1
C18	Debelo črevo Colon	888	230	5	0	0	7	136	60	0	7	0	14	0	1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	468	175	2	0	0	2	147	18	0	1	0	5	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	259	54	0	0	0	35	7	12	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	40	0	0	0	11	12	12	0	4	0	1	0	0
C25	Trebušna slinavka Pancreas	442	143	0	0	0	40	55	37	0	4	0	6	0	1
C32	Grlo Larynx	106	7	0	0	0	0	6	1	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1602	536	0	150	0	0	237	145	0	0	1	0	0	3
C43	Maligni melanom kože Malignant melanoma of skin	636	59	0	0	0	0	59	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3608	26	1	0	0	4	2	16	2	0	0	0	0	1
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	76	15	0	0	0	2	13	0	0	0	0	0	0	0
C50	Dojka Breast	1579	1425	17	1	9	0	995	327	0	48	1	18	2	7
C53	Maternični vrat Cervix uteri	104	5	0	0	0	0	4	1	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	390	85	0	0	0	1	63	21	0	0	0	0	0	0
C56	Jajčnik Ovary	163	114	0	0	0	0	86	27	0	1	0	0	0	0
C61	Prostata Prostate	1565	438	19	0	16	73	134	56	18	15	33	35	27	12
C62	Modo Testis	115	66	0	0	0	1	65	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	394	44	0	0	0	2	35	6	0	0	0	1	0	0
C67	Sečni mehur Bladder	316	69	0	0	0	2	47	13	1	1	1	3	0	1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	173	83	0	0	0	1	82	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	202	190	15	0	0	22	140	9	0	0	0	0	2	2
C81	Hodgkinov limfom Hodgkin's lymphoma	63	57	0	0	0	6	50	0	0	0	0	0	0	1
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	480	274	1	0	0	21	242	4	2	1	2	1	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	145	114	13	0	2	55	0	26	1	6	6	4	0	1
C91–C95	Levkemije Leukaemias	385	173	15	0	0	116	5	26	2	2	3	1	0	3

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat
 Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov
 Less than 10 patients were treated in individual institution

Breme najpogostejših rakov


Cancer Fact Sheets

Vsi raki / All cancer sites (C00–C96)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	8345	7218	15563
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	38,3	29,9	33,9
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	810,5	693,4	751,6
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	403,1	315,6	352,3
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,5*	2,6*	2,0*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,6*	1,5*	0,4*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	3538	2794	6332
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	15,3	9,6	12,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	343,6	268,5	305,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	152,4	91,6	117,8
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	0,9*	1,1*	1,0*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,7*	-0,6	-1,1*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	63907	72277	136184
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	6110,6	6926,6	6518,1
1-letna prevalenca / 1-year prevalence	7052	6651	13703
5-letna prevalenca / 5-year prevalence	27726	26015	53741

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Prostata / Prostate (C61)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male
Število novih primerov v enem letu / Number of new cases per year	1676
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	20,1
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	1.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	25,0
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	10,3
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	162,8
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	78,0
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	0,7
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,6
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)	
Število smrti v enem letu / Number of deaths per year	434
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	12,3
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	42,1
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	15,4
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	2,3*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,2
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)	
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	15922
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	1522,4
1-letna prevalenca / 1-year prevalence	1498
5-letna prevalenca / 5-year prevalence	7217

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrlijivost Mortality Slovenija 1985–2019




Pljuča in sapnik / Lung and trachea (C33, C34)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	975	561	1536
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	11,7	7,8	9,9
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	3.	4.	3.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	14,5	10,1	12,5
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	5,8	3,1	4,4
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	94,6	53,9	74,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	46,0	23,8	33,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,6*	5,9*	3,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,6	4,5*	1,3*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	797	420	1217
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	22,5	15,0	19,2
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	4,4	2,1	3,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	77,4	40,4	58,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	36,2	16,1	25,2
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,4	4,1*	1,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,8*	2,5*	1,0*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	2346	1666	4012
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	224,3	159,7	192,0
1-letna prevalenca / 1-year prevalence	606	410	1016
5-letna prevalenca / 5-year prevalence	1534	1150	2684

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Dojka / Breast (C50)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Ženske / Female
Število novih primerov v enem letu / Number of new cases per year	1454
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	20,1
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	2.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	26,1
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	8,0
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	139,7
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	74,0
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,6*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,7*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)	
Število smrti v enem letu / Number of deaths per year	431
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	15,4
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,6
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	41,4
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	14,7
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	1,0
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,9
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)	
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	19316
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	1851,1
1-letna prevalenca / 1-year prevalence	1515
5-letna prevalenca / 5-year prevalence	6456

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrlijivost Mortality Slovenija 1985–2019




Debelo črevo in danka / Colon and rectum (C18–C20)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	812	570	1382
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	9,7	7,9	8,9
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	4.	3.	5.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	12,1	10,2	11,2
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	4,4	2,5	3,4
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	78,9	54,8	66,8
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	37,7	21,5	28,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-3,0*	-2,1*	-2,6*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-5,3*	-3,7*	-4,7*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	431	307	738
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	12,2	11,0	11,7
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,8	0,9	1,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	41,8	29,5	35,6
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	17,9	8,7	12,7
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,8	-2,2*	-1,4*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,5*	-4,4*	-3,7*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	6902	5325	12227
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	660,0	510,3	585,2
1-letna prevalenca / 1-year prevalence	648	504	1152
5-letna prevalenca / 5-year prevalence	2665	1859	4524

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Koža, razen melanoma / Skin, non-melanoma (C44)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	1628	1638	3266
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	19,5	22,7	21,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	2.	1.	1.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	/	/	/
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	7,7	6,5	7,1
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	158,1	157,4	157,7
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	72,9	61,5	65,8
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	5,1*	5,8*	5,4*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	2,5*	4,6*	3,5*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	21	24	45
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	0,6	0,8	0,7
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,04	0,01	0,02
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	2,1	2,3	2,2
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	0,7	0,4	0,5
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-	-	-
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-	-	-
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	16279	17900	34179
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	1556,6	1715,4	1635,9
1-letna prevalenca / 1-year prevalence	1762	1773	3535
5-letna prevalenca / 5-year prevalence	7258	7501	14759

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Kožni melanom / Malignant melanoma of skin (C43)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	310	283	593
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	3,7	3,9	3,8
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	6.	6.	6.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	4,6	5,1	4,8
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	1,8	1,6	1,7
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	30,1	27,2	28,6
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	16,4	15,3	15,6
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,8*	2,4*	2,6*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	0,5	1,6	1,0*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	69	54	123
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	1,9	1,9	1,9
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,4	0,2	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	6,7	5,2	5,9
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	3,2	2,0	2,5
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-1,1	0,5	-0,4
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,7*	-2,5	-3,1*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	3379	4050	7429
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	323,1	388,1	355,6
1-letna prevalenca / 1-year prevalence	309	309	618
5-letna prevalenca / 5-year prevalence	1346	1280	2626

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Glava in vrat / Head and neck (C00–C14, C30–C32)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	369	102	471
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	4,4	1,4	3,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.	15.	7.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	5,5	1,8	3,8
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	2,4	0,6	1,5
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	35,8	9,8	22,8
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	19,4	4,9	11,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-1,1	1,4	-0,6
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,8*	0,1	-2,2*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	169	39	208
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	4,8	1,4	3,3
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,0	0,2	0,6
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	16,5	3,7	10,1
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	8,3	1,6	4,8
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-2,9*	0,3	-2,3*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-4,9*	-0,9	-4,1*
PREVALENCA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	2739	947	3686
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	261,9	90,8	176,4
1-letna prevalenca / 1-year prevalence	312	88	400
5-letna prevalenca / 5-year prevalence	1138	358	1496

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019




Maternično telo / Corpus uteri (C54)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Ženske / Female
Število novih primerov v enem letu / Number of new cases per year	362
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	5,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	6,5
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	2,0
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	34,7
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	16,3
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,9*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	0,9
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)	
Število smrti v enem letu / Number of deaths per year	69
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,5
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	6,6
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	2,2
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	5,8*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	6,4*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)	
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	4984
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	477,6
1-letna prevalenca / 1-year prevalence	358
5-letna prevalenca / 5-year prevalence	1476

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrlijivost Mortality Slovenija 1985–2019




Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)


INCIDENCA (povprečje v obdobju 2015–2019) / INCIDENCE (average during 2015–2019)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	226	218	444
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	2,7	3,0	2,9
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	10.	7.	9.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	3,4	3,9	3,6
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	1,3	1,1	1,2
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	21,9	20,9	21,4
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	11,6	9,2	10,3
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	3,3*	4,1*	3,7*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,5	3,1*	2,3*
UMRLJIVOST (povprečje v obdobju 2015–2019) / MORTALITY (average during 2015–2019)			
Število smrti v enem letu / Number of deaths per year	89	89	178
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,5	3,2	2,8
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,4	0,3	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	8,7	8,6	8,6
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	3,7	2,5	3,1
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	6,5*	4,3*	5,4*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	3,6	2,8	3,2*
PREVALENCIA (na dan 31.12.2019) / PREVALENCE (on December 31, 2019)			
Število živih oseb z diagnozo raka ob koncu leta 2019 (prevalenca) / Persons living with cancer at the end of 2019 (prevalence)	1812	1851	3663
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2019	173,3	177,4	175,3
1-letna prevalenca / 1-year prevalence	191	211	402
5-letna prevalenca / 5-year prevalence	742	749	1491

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2019



Umrljivost Mortality Slovenija 1985–2019



Definicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA:
<http://www.slora.si/definicije-kazalnikov-in-metod>.

- Incidenca** Število vseh na novo ugotovljenih primerov raka v točno določeni populaciji v enem koledarskem letu.
- Umrljivost** Število vseh umrlih za določeno boleznijo v točno določeni populaciji v enem koledarskem letu.
- Prevalenca** Število vseh bolnikov z določeno boleznijo, ki so bili živi na izbrani datum (ponavadi zadnji dan v letu). Glede na čas, kdaj so zboleli, ločimo:
- Celotna prevalenca upošteva vse bolnike z rakom ne glede na to, kdaj so zboleli.
 - Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v točno določenem obdobju pred datumom izračuna. Na primer, v enoletno delno prevalenco so vključeni bolniki, ki so zboleli leto dni pred datumom izračuna ter so na ta datum še živi.
- Preživetje** Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V poročilu podajamo čisto preživetje, izračunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proučevanega raka (hipotetičen primer, v katerem ne umirajo zaradi drugih vzrokov smrti).
- Groba stopnja** Incidenca ali umrljivost, preračunani na velikost opazovane populacije. Običajno je izražena na 100.000 prebivalcev.
- Starostno standardizirana stopnja** Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, če bi bila starostna struktura te populacije enaka kot je v standardni populaciji. Uporabljene so tri standardne populacije: svetovna (Segi 1961), evropska (Doll 1976) in slovenska standardna populacija (Popis 2002).
- Kumulativna stopnja** Kumulativna incidenčna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje.
- Kumulativno tveganje** Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), če ne umre prej zaradi drugih vzrokov.
- Ocena incidence** Ocena števila novih primerov za tekoče koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vključeni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo.

Definitions of indicators and methods are explained in detail on web portal SLORA:
<http://www.slora.si/en/definicije-kazalnikov-in-metod>.

Incidence Number of all newly diagnosed cancer cases that develop in a defined population in one calendar year.

Mortality Number of all patients who died because of certain disease in a defined population in one calendar year.

Prevalence Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnosis we distinguish:

- Lifetime prevalence is defined as the number of all persons ever diagnosed with cancer and being alive at a specific time date.
- Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation.

Survival In groups of patients, survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients' survival from cancer only (all other causes of death excluded).

Crude rate Incidence or mortality calculated per observed population, usually expressed per 100.000 population.

Age-standardized rate Age-standardization tells what the crude rate would be in observed population, if its age structure were the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002).

Cumulative rate The cumulative incidence or mortality rate is a special form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk.

Cumulative risk Cumulative risk is expressed in percentages and interpreted as the risk an individual would have of developing the disease in question during a certain age range (e.g. up to the age of 74), if there were no other causes of death.

Estimation of incidence Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years.

